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Objectives: Our previous study qualitatively explored decision-making about ex-
posure to potential risk of infection in young people with CF, highlighting the role
of competing social demands and gaps in knowledge. The current study extended
this, exploring judgements about risk in a national sample.
Methods: People with CF were invited to complete an online survey via social
media forums hosted by the UK CF Trust. This focused on participants’ decisions in
4 hypothetical risk scenarios, beliefs underlying decisions, and perceived importance
of different sources of information.
Results: 75 respondents; mean age 24; 65% female. Many were less aware of
environmental risks such as cleaning stables (72% saw this as medium-no risk),
but better informed about person-person risk (only 13% would meet another person
with CF, 3% if they have cepacia), though even here there were gaps in knowledge
(32% did not know what cepacia was). Decisions were responsive to available risk
information: 45% would not visit a friend on a ward where there was MRSA, and
this rose to 73% if the friend had MRSA. Uncertainty about their own infection
status was also important. The most trusted sources of advice were verbal and
written information from the team, followed by the CF Trust and the internet.
Conclusion: Though this sample was CF Trust forum users and arguably more
active than most with CF, knowledge still varied widely. Young people with CF
make active decisions about exposure to risk of infection, but these are not always
based on reliable knowledge, particularly of environmental risk. This is an ongoing
study. Full results and thematic analyses of narrative responses will be presented.
46 Microbiological airway flora in children with cystic fibrosis in the
first year of life (To treat or not to treat, that’s the question!)
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In children with cystic fibrosis (CF) pulmonary microbial colonization and infection
are important prognostic factors. In Germany a national CF newborn screening does
not exist by now and only little is known about the microbial respiratory flora of
children with CF in the first years of life.
In Dresden a regional newborn screening program for eastern Saxony exists
since 1996. Thus, a microbiological monitoring for patients with CF was already
performed from diagnosis in the first month of life throughout babyhood and we
collected data from 1997 on.
In the following, we want to demonstrate the microbial colonization of 55 patients
in our center in their first year of life. In all patients we found bacteria other than
normal flora of mouth and throat. Most commonly we detected Staphylococcus
aureus, Haemophilus influenzae and Escherichia coli, but also a variety of many
other such as Klebsiella, Serratia, Streptococcus, Enterobacter, Enterococcus and
Acinetobacter species, Bacillus cereus, Branhamella catarrhalis, and more. We
also detected Pseudomonas aeruginosa and other Pseudomonas species already in
patients at this young age. In several patients we found fungi in the throat swab,
such as Aspergillus, Candida and Saccharomyces species.
Most of the patients needed antibiotic therapy in their first year of life due to
pulmonary exacerbation, but the clinical symptoms in many cases did not correlate
with the microbiological findings by throat swab.
With the introduction of a national newborn screening program for CF hopefully
end of this year, we will have to discuss the influence of these bacterial findings in
the first year of life on the prognosis and the need for treatment.
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Objectives: The identification of certain bacterial species from the sputum of
patients with CF carries prognostic significance so accurate identification is es-
sential. MALDI-TOF technology promises rapid and accurate identification of the
sometimes difficult bacteria Pseudomonas aeruginosa, members of the Burkholderia
cepacia and other non fermenting organisms. We have compared results from
bioMérieux MALDI-TOF and Bruker MALDI-TOF for the Burkholderia cepacia
complex (Bcc).
Methods: A range of organisms from patients attending a Paediatric CF Centre
were identified using 2 MALDI-TOF systems and in-house molecular methodology
with referral of isolates to a Reference Laboratory if appropriate.
Results: Five isolates categorised as P. aeruginosa on the bioMérieux system were
identified by in-house 16s ribosomal DNA sequencing or Reference Laboratory
testing as P. nitroreducens. On retesting on the Bruker MALDI-TOF all 5 strains
were identified as P. nitroreducens. Ninety-four PCR-confirmed Bcc strains were
tested in parallel and both MALDI-TOF machines categorised them within the
cepacia complex. At Genomovar level, B. multivorans and B. vietnamiensis gave
concordant results on the 2 systems. All of 28 B. cepacia identified on the
bioMérieux MALDI-TOF were B. cenocepacia according to Bruker.
Conclusion: Misidentification of P. aeruginosa and B. cenocepacia is unacceptable
as incorrect segregation and antibiotic management of patients would ensue.
Refinement and compatibility of MALDI-TOF databases is essential before this
technology can replace current DNA based identification methods and needs to be
supported by relevant and robust EQA schemes.
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Objectives: CF is associated with altered digestive function and thus nutrient
availability for gut microbes in addition to altered gut microbiota, compared with
healthy controls. Equally intensive antibiotic and nutritional therapy may further
compound this. We present results from the largest CF gut microbiota study to
date.
Methods: The gut microbiota of 43 stable adults with CF was compared to 69 age-
matched controls. DNA was extracted from faecal samples and the V4 region of the
16S rRNA gene was sequenced using 454-pyrosequencing. Results were correlated
with baseline %FEV1 results and to total courses of IVs in the previous 12 months.
Results: The gut microbiota diversity of patients with CF was significantly reduced
compared to controls (p< 0.05 for all a diversity tests). Significantly increased
proportions of Firmicutes (p = 0.029) and decreased Bacteroidetes (p< 0.001) oc-
curred in those with CF compared to controls. There were significant reductions
in proportions of bacteria associated with gut health in those with CF, including
decreased Faecalibacterium, Roseburia and Bifidobacterium (p< 0.001). A negative
correlation between the number of IV courses and gut diversity [Simpson’s diversity
index: correlation coefficient (r) = −0.383, p = 0.0111] and a positive correlation
between FEV1 and gut diversity (Simpson’s diversity index: r = 0.47, p = 0.0015)
was found in those with CF.
Conclusion: This study highlights that patients with CF have an altered gut
microbiota which correlates with clinical outcomes. Further longitudinal studies will
enable us to interrogate the causality of such microbiota alterations and determine
the potential role of probiotics in CF therapy.
